Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 2/2011

01.04.2011

Imaging of Coronary Inflammation with FDG-PET: Feasibility and Clinical Hurdles

verfasst von: Ian S. Rogers, Ahmed Tawakol

Erschienen in: Current Cardiology Reports | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Conventional algorithms and noninvasive imaging tests for the identification of stable, hemodynamically significant coronary artery disease offer little insight into the detection of potentially vulnerable and inflamed coronary plaques, those most likely to rupture and cause acute coronary syndromes. Positron emission tomography (PET) with fluorodeoxyglucose (FDG) serves as a potential novel modality for the identification of plaque inflammation, as initial studies in animal and human studies have demonstrated that FDG uptake correlates with macrophage accumulation and inflammation. Therapy with anti-inflammatory agents has also been demonstrated in the arterial vasculature to reduce plaque FDG uptake. Although imaging of coronary inflammation with FDG-PET holds tremendous promise, several hurdles remain to be surmounted prior to widespread clinical application.
Literatur
1.
Miniño AM, Xu J, Kochanek KD, Tejada-Vera B. Death in the United States, 2007. NCHS Data Brief. 2009 Dec;(26):1–8.
2.
Naghavi M, Libby P, Falk E, Casscells SW, et al. From Vulnerable Plaque to Vulnerable Patient A Call for New Definitions and Risk Assessment Strategies: Part I. Circulation. 2003;108:1664–72.CrossRefPubMed
3.
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–75.PubMed
4.
Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62.CrossRefPubMed
5.
Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–71.PubMed
6.
Schlendorf KH, Nasir K, Blumenthal RS. Limitations of the Framingham risk score are now much clearer. Prev Med. 2009;48:115–6.CrossRefPubMed
7.
Karim R, Hodis HN, Detrano R, et al. Relation of Framingham risk score to subclinical atherosclerosis evaluated across three arterial sites. Am J Cardiol. 2008;102:825–30.CrossRefPubMed
8.
Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184:201–6.CrossRefPubMed
9.
Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809–13.CrossRefPubMed
10.
Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104:14S–8.CrossRefPubMed
11.
Davies MJ, Woolf N, Rowles P, Richardson PD. Lipid and cellular constituents of unstable human aortic plaques. Basic Res Cardiol. 1994;89:33–9.PubMed
12.
Kolodgie FD, Burke AP, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001;16:285–92.CrossRefPubMed
13.
Kaim AH, Weber B, Kurrer MO, et al. Autoradiographic quantification of 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology. 2002;223:446–51.CrossRefPubMed
14.
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.PubMed
15.
Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J. 1989;261:211–8.PubMed
16.
Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine induced inflammatory tissue. J Nucl Med. 1995;36:1301–6.PubMed
17.
18.
Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr. 1999;23:16–8.CrossRefPubMed
19.
Meller J, Altenvoerde G, Munzel U, et al. Fever of unknown origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27:1617–25.CrossRefPubMed
20.
Blockmans D, Maes A, Stroobants S, et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology. 1999;38:444–7.CrossRefPubMed
21.
Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol. 2000;86:3J–9.CrossRefPubMed
22.
Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:7–29.CrossRefPubMed
23.
Strauss HW, Dunphy M, Tokita N. Imaging the vulnerable plaque: a scintillating light at the end of the tunnel? J Nucl Med. 2004;45:1106–7.PubMed
24.
Seshiah PN, Kereiakes DJ, Vasudevan SS, et al. Activated monocytes induce smooth muscle cell death: role of macrophage colony-stimulating factor and cell contact. Circulation. 2002;105:174–80.CrossRefPubMed
25.
Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxy glucose positron emission tomography. J Nucl Cardiol. 2005;12:294–301.CrossRefPubMed
26.
Ogawa M, Ishino S, Mukai T, et al. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004;45:1245–50.PubMed
27.
Aziz K, Berger K, Claycombe K, et al. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation. 2008;117:2061–70.CrossRefPubMed
28.
Ogawa M, Magata Y, Kato T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845–50.PubMed
29.
Davies JR, Izquierdo-Garcia D, Rudd JH, et al. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. Int J Cardiovasc Imaging. 2010;26:41–8.CrossRefPubMed
30.
Worthley SG, Zhang ZY, Machac J, et al. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiol Imaging. 2009;25:251–7.CrossRef
31.
Théron J, Tyler JL. Takayasu’s arteritis of the aortic arch: endovascular treatment and correlation with positron emission tomography. AJNR Am J Neuroradiol. 1987;8:621–6.PubMed
32.
Yun M, Yeh D, Araujo L, et al. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med. 2001;26:314–9.CrossRefPubMed
33.
Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562–9.CrossRefPubMed
34.
Joly L, Djaballah W, Koehl G, et al. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification. Eur J Nucl Med Mol Imaging. 2009;36:979–85.CrossRefPubMed
35.
Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging. 2009;2:107–15.CrossRefPubMed
36.
Kim TN, Kim S, Yang SJ, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142–8.CrossRefPubMed
37.
Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.CrossRefPubMed
38.
Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.CrossRefPubMed
39.
Davies JR, Rudd JH, Fryer TD, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642–7.CrossRefPubMed
40.
Silvera SS, Aidi HE, Rudd JH, et al. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009;207(1):139–43.CrossRefPubMed
41.
Derdelinckx I, Maes A, Bogaert J, Mortelmans L, Blockmans D. Positron emission tomography scan in the diagnosis and follow-up of aortitis of the thoracic aorta. Acta Cardiol. 2000;55:193–5.CrossRefPubMed
42.
Meller J, Strutz F, Siefker U, et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging. 2003;30(5):730–6.CrossRefPubMed
43.
Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003;229(3):831–7.CrossRefPubMed
44.
Graebe M, Pedersen SF, Borgwardt L, et al. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37(6):714–21.CrossRefPubMed
45.
Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50(9):892–6.CrossRefPubMed
46.
Tahara N, Kai H, Ishibashi M, et al. Simvastatin Attenuates Plaque Inflammation: Evaluation by Fluorodeoxyglucose Positron Emission Tomography. J Am Coll Cardiol. 2006;48(9):1825–31.CrossRefPubMed
47.
Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278–84.PubMed
48.
Alexanderson E, Slomka P, Cheng V, et al. Fusion of positron emission tomography and coronary computed tomographic angiography identifies fluorine 18 fluorodeoxyglucose uptake in the left main coronary artery soft plaque. J Nucl Cardiol. 2008;15:841–3.PubMed
49.
•• Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3(4):388–97. This research found that aortocoronary FDG uptake was higher in the subjects who presented with ACS, compared to subjects presenting with stable angina.CrossRefPubMed
50.
Achenbach S, Ropers D, Holle J, et al. In-plane coronary arterial motion velocity: measurement with electron-beam CT. Radiology. 2000;216:457–63.PubMed
51.
Lu B, Mao SS, Zhuang N, et al. Coronary artery motion during the cardiac cycle and optimal ECG triggering for coronary artery imaging. Invest Radiol. 2001;36:250–6.CrossRefPubMed
52.
Büther F, Dawood M, Stegger L, et al. List mode-driven cardiac and respiratory gating in PET. J Nucl Med. 2009;50(5):674–81.CrossRefPubMed
53.
54.
Stanley WCLG, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243–57.CrossRefPubMed
55.
de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98–101.CrossRefPubMed
56.
Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77.PubMed
57.
• Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–6. This research found significantly lower myocardial FDG uptake in subjects instructed to eat a VHFLCPP diet prior to FDG imaging.CrossRefPubMed
58.
Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.CrossRefPubMed
59.
•• Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611–20. This research found that asymptomatic subjects with an elevated mean arterial FDG target-to-background ratio had a higher rate of subsequent vascular events.CrossRefPubMed
Metadaten
Titel
Imaging of Coronary Inflammation with FDG-PET: Feasibility and Clinical Hurdles
verfasst von
Ian S. Rogers
Ahmed Tawakol
Publikationsdatum
01.04.2011
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 2/2011
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-011-0168-3

Weitere Artikel der Ausgabe 2/2011

Current Cardiology Reports 2/2011 Zur Ausgabe

ReviewPaper

Risk Scores for Predicting Outcomes in Valvular Heart Disease: How Useful?

ReviewPaper

The Heterogeneous Biomechanics and Mechanobiology of the Mitral Valve: Implications for Tissue Engineering

ReviewPaper

Percutaneous Mitral Repair: Patient Selection, Results, and Future Directions

ReviewPaper

Fatty Acid Imaging of the Heart

ReviewPaper

Variation of Heart-to-Mediastinal Ratio in 123I-mIBG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections

ReviewPaper

Novel F-18–Labeled PET Myocardial Perfusion Tracers: Bench to Bedside

Neu im Fachgebiet Kardiologie

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise